Kraig Biocraft Laboratories' Spider Silk is on Track for Large Scale Production
March 20 2014 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the
leading developer of advanced spider silk based fibers, today
announced that its scientific evaluation team performed an onsite
assessment and evaluation, at the request of the Company, of its
genetically engineered recombinant spider silk, Monster Silk™,
production ramp up. This production ramp up follows closely on the
heels of the Company's successful pilot production program, which
finished in late 2013. The scientific evaluation team reported that
the ramp up program is on track for large scale production of
Monster Silk™. The team's report also included specific
recommendations for accelerating commercial scale production and
for completing the transition from pilot production to commercial
scale production.
"The scientific evaluation team's findings reinforce our belief
that this important program is working and warrants that we commit
additional resources to our scale up of Monster Silk™ production.
This evaluation encourages us that we are on the right track to
achieve our goal of large scale production. More importantly, the
team found areas where we can improve our production efficiency in
order to reach that goal. We have already started to put these
plans in place to strengthen the Monster Silk™ production program,"
said Company Founder and CEO, Kim K. Thompson.
The goal of this program is to produce Monster Silk™ in metric
ton quantities.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully
reporting biotechnology company is the leading developer of
genetically engineered spider silk based fiber technologies. The
Company has achieved a series of scientific breakthroughs in the
area of spider silk technology with implications for the global
textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "if," "develops," "researching,"
"research," "pilot," "potential," "could" or other words or phrases
of similar import. Forward looking statements include descriptions
of the Company's business strategy, outlook, objectives, plans,
intentions and goals. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Apr 2023 to Apr 2024